Schizophrenia/Psychosis

The RISE study results look promising.

There is much to look forward to in the realm of improved treatments for patients with psychiatric illness.

Our basic science knowledge of the brain continues to explode beyond what science fiction of the past has predicted.

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Navigating the treatment options for comorbid schizophrenia and alcohol use

Findings bring us closer to understanding schizophrenia that may enable clinicians to target symptoms.

Karuna Therapeutics shared exciting results from a Phase 2 trial on their lead agent.

Mutations in PCM1, a gene crucial to neuronal cilia function, have been connected with schizophrenia, according to a recent study.

Listen to discussion on results from a recent Phase 1b clinical trial.

Joining together to discuss psychosis, 3 British experts discuss various ways to respond to and help people who have experienced both trauma and psychosis.

New-onset symptoms of anxiety and depressive symptoms have erupted in the wake of the COVID-19 pandemic, yet even in the middle of the pandemic, there are reasons to be grateful.

A recent drug trial yields encouraging results.

COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.

Recent research sheds light on the role of adjunctive long-acting injectable antipsychotics in treatment-resistant schizophrenia.

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.

New research underlies the need for addressing identity in young patients during early stages of psychosis.